These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Methylphenidate transdermal system: clinical applications for attention-deficit/hyperactivity disorder.
    Author: Elia J, Wilson Z, La Porta LS, Algon SA, Prowler ML, Cartwright ST, McKenna PA, Laracy S, Takeda T, Borgmann-Winter K.
    Journal: Expert Rev Clin Pharmacol; 2011 May; 4(3):311-28. PubMed ID: 22114778.
    Abstract:
    The methylphenidate transdermal system (MTS) provides a novel method of delivery for methylphenidate, a well-studied and effective medication for attention-deficit/hyperactivity disorder. The MTS achieves two major goals. First, the delivery system allows for administration throughout the day with a single patch, thus improving adherence. Second, it is the first approved attention-deficit/hyperactivity disorder medication that is not administered orally, thus bypassing gastrointestinal absorption and first-pass metabolism through the enteric circulation. In this article, we review the current data on MTS, including preclinical, clinical and post-marketing studies, and compare efficacy and tolerability to currently available treatments.
    [Abstract] [Full Text] [Related] [New Search]